J.P. Morgan Making Sense · · 21 min
Healthcare’s next wave: AI, innovation and the future of access
With Chris Schott, Robbie Marcus
ChorusBring the market's conversation to your AI. Learn more
Summary
On J.P. Morgan Making Sense, Chris Schott and Robbie Marcus surveyed healthcare's near-term outlook, contrasting a strong pharma innovation cycle with a weak medtech and provider backdrop. Schott argued that pharma is entering a major innovation wave led by oncology breakthroughs, that China is rapidly becoming a major source of new drugs, and that GLP-1 obesity drugs have a long growth runway as prices fall and oral options scale; he also saw Merck's Keytruda franchise at risk of eventual replacement by newer ADC and bispecific therapies. Marcus described medtech procedure volumes at a trough, pressured by high rates, Medicaid and ACA coverage cuts, and cash-pay elective procedures, with hope rather than conviction for a 2027 bottom. Both viewed AI as useful now in clinical data and regulatory filings but early in discovery, and Schott judged the 2026 drug pricing deal and a healthy pharma M&A backdrop as stabilising factors.
Key takeaways
- Robbie Marcus on Healthcare system & insurers: Medtech is at a trough: rates, funding changes and weak innovation hurt procedure volumes; hopes 2027 bottoms.
- Chris Schott (bearish on Merck & Co.): Keytruda, the largest oncology launch, will likely be replaced by much better therapies in 5-7 years.
- Chris Schott on GLP-1s & obesity drugs: GLP-1 penetration is still early; better drugs and cheaper access point to a lot of growth ahead.
- Robbie Marcus on Healthcare system & insurers: ACA subsidy cuts and Medicaid tightening are slowing elective procedure volumes; more Medicaid declines next year.
- Chris Schott on Pharma & biotech: China's share of new drugs has risen from 5-10% to about 50% in a decade, reshaping the industry.
What was said, by company and theme
12 views from 2 speakers. Every quote is checked against the episode's transcript (how).
Merck & Co.
Across the shows: 4 speakers in other episodes, 3 bullish and 1 bearish calls, past 30 days
Where everyone stands on Merck & Co.
Chris Schott · J.P. MorganBearish
Keytruda, the largest oncology launch, will likely be replaced by much better therapies in 5-7 years.
Schott calls Keytruda the largest oncology product ever launched. He argues breakthroughs in newer technologies such as ADCs and bispecifics are improving standard of care in big tumor types like lung cancer, the largest cancer by incidence. He thinks there is a good chance Keytruda gets replaced within five to seven years by much better therapies. The bearish read for Merck is implied by this franchise-erosion argument rather than stated outright.
“Keytruda, it's the largest oncology product ever launched. We think there's a good chance that that drug gets replaced in the next five or seven years with actually much better therapies.”at 3:44
Pharma & biotech
Where everyone stands on Pharma & biotech
Chris Schott · J.P. Morgan
Pharma is in a significant, robust R&D innovation cycle, shifting focus away from patent expirations.
Schott's group has long balanced new launches against patent expirations, and for most of the last decade the focus was on expirations. He says that focus is now pivoting to a significant innovation cycle across therapeutic areas, with some of the most robust R&D he has seen in his 25-plus years covering the group, and expects this to become the main topic for biotech and pharma investors.
“I'm actually seeing that focus though really starting to pivot, so what we're seeing now is a pretty significant innovation cycle across the industry.”at 1:31
Chris Schott · J.P. Morgan
The US-to-global pricing deal with the administration is a good outcome, but pricing debate may return in 2028.
About a year ago the industry struck a deal with the Trump administration to ease into flatter developed-market pricing. It grandfathers legacy products and commits new products to a more globally flat price point. Schott says this was viewed as a great outcome, removing a long-running overhang. He thinks it is unlikely to change under a new Congress, but the debate could return under a new administration in 2028 or 2029. This is the policy topic he spends most time on.
“That was viewed as a great outcome for the industry, and kind of leaving what's long been this overhang of end topic of debate for the sector.”at 15:54
Chris Schott · J.P. Morgan
China's share of new drugs has risen from 5-10% to about 50% in a decade, reshaping the industry.
Schott says a decade ago maybe 5-10% of new drugs came from China and that the share is now pushing toward 50%, which he calls stunning. He expects faster innovation, which is good for patients, more partnership opportunities for larger-cap companies developing drugs globally, and more competition for everyone. He thinks both the industry and policymakers will have to adapt to this emerging ecosystem.
“if you look a decade ago, maybe five or 10% of new drugs came out of China. We're looking at that number pushing towards 50% today”at 19:51
Healthcare system & insurers
Where everyone stands on Healthcare system & insurers
Robbie Marcus · J.P. Morgan
Medtech is at a trough: rates, funding changes and weak innovation hurt procedure volumes; hopes 2027 bottoms.
Marcus says medtech, normally a steady grower, is at a trough. Financial conditions, government changes to health funding and about two years of little new innovation have produced negative estimate revisions across the group. High interest rates make patient co-pays harder to pay, so procedure volumes face pressure for the first time since the global financial crisis. He is looking into 2027 and hopes things are bottoming and improving, though this is framed as hope rather than a firm call.
“we're at a trough now where the financial conditions around the world, some of the government changes in funding for health care, and just a lack of new innovation over the last twenty four months has left med tech where we've seen negative revisions across the group”at 2:05
Robbie Marcus · J.P. Morgan
Devices win adoption when they balance patient outcomes, hospital margins and payer cost; outcomes come first.
Marcus says a new device becomes routine care when it meets three tests. Outcomes for patients come first. The hospital must be able to at least not lose money, given reimbursement rates. Payers must find the cost reasonable. Cheap devices with worse outcomes are poorly adopted in developed markets, and so are good-outcome devices that are unprofitable for hospitals. Cardiology examples such as structural heart, electrophysiology and ablation are safer and faster but priced higher, giving hospitals better profits but less system savings.
“if you can check all three of those boxes, we're seeing it. That's really what drives it. But it's obviously patients first. So the outcomes are the most important.”at 10:12
Robbie Marcus · J.P. Morgan
ACA subsidy cuts and Medicaid tightening are slowing elective procedure volumes; more Medicaid declines next year.
The budget bill cut Affordable Care Act subsidies in 2026 and tightens Medicaid qualifications from 2027. Combined with higher rates, inflation and more out-of-pocket pay, this is the first time in many years that procedure volume growth has slowed in elective procedures such as knee care and cataract lens purchases, which are all cash pay. Marcus expects Medicaid covered patients to decline further next year. He says there are no material changes expected from the midterm election, but a new administration in 2028 could improve coverage.
“we've seen for the first time in many, many years, deceleration in procedure volume growth in some of the, more elective procedures like knee care, lens purchases, intraocular lenses for cataracts, which is all cash pay.”at 17:01
GLP-1s & obesity drugs
Where everyone stands on GLP-1s & obesity drugs
Chris Schott · J.P. Morgan
GLP-1 penetration is still early; better drugs and cheaper access point to a lot of growth ahead.
Penetration is high single digits in the US and around 2% internationally, so Schott views the category as early. Growth drivers are better drugs and affordability. Oral GLP-1s, launched in 2026, already make up about 25% of the market by volume. Retatrutide targets three incretins and could become best-in-class for faster, greater weight loss. Amylin-based drugs are better tolerated because they avoid GI side effects. Seniors can now get the drugs for $50 a month since July, and over a million have started in a couple of months. Schott says combining affordability and innovation means a ton of growth ahead.
“We're talking about penetration rates that are high single digits in The US, more like 2% internationally. So, I think we're pretty early in this journey of what GLP-1s will do to the broader market.”at 6:50
Chris Schott · J.P. Morgan
GLP-1 prices will keep falling, with double-digit annual price erosion expected from 2027.
Affordability is a hurdle for GLP-1 adoption because many patients still pay out of pocket. Prices came down about 20% in 2026. Schott says he could see double-digit annual price erosion in 2027 and beyond. This is a forecast for a pricing trend that sits alongside rising volumes, and it does not depend on any specific company.
“Price came down about 20% in 2026. I think we could see, honestly, double digit annual price erosion '27 and beyond.”at 8:32
Enterprise AI adoption & AI software
Where everyone stands on Enterprise AI adoption & AI software
Chris Schott · J.P. Morgan
AI already speeds clinical data analysis and filings; whether it transforms early drug discovery is unknown for 3-5 years.
Schott says the AI conversation in drug development is nuanced. Benefits already show up in clinical data analysis and in assembling filings to get drugs to market sooner. Patent protection lasts only 15-18 years, so carving six or 12 months off development creates real value. Early-stage discovery and molecule design is less proven. He thinks it is too early to say whether AI will be transformational, and expects three to five years before there is a better answer. Smaller diseases could get more resources, while big areas like cancer and GLP-1s may see less benefit because they already get heavy research focus.
“We're already seeing a benefit here. You can analyze clinical data faster. You can pull together filings to get drugs to market sooner.”at 11:21
Robotics & autonomous vehicles
Where everyone stands on Robotics & autonomous vehicles
Robbie Marcus · J.P. Morgan
Fully autonomous robotic surgery is more than three to five years away; AI already aids surgical robots.
Marcus says robots already use AI to remove hand tremor and that digital overlays and automatic suturing are close on the horizon. He thinks robots doing surgery on their own without human intervention is still more than three to five years away. He also cites AI improving medical imaging, AI-driven insulin dosing from connected pumps and CGMs, and swallowable AI camera pills that could replace scopes.
“The good news at least, for clinicians and health care providers is I think we're probably even more than three to five years away from having a robot do a surgery single handedly without the intervention of a human.”at 12:44
IPOs, M&A & deal activity
Where everyone stands on IPOs, M&A & deal activity
Chris Schott · J.P. Morgan
Pharma is defensive and not rate-sensitive, so M&A and bolt-on deals should be healthy and could accelerate.
Schott says pharma is not very economically or rate sensitive and is defensive, especially with good fundamentals. He expects a fairly healthy M&A environment. Companies have new products and some remaining patent expirations, and the innovation is industry-wide. Smaller and mid-cap companies more exposed to rates may make partnering or acquiring their assets more attractive, so bolt-on acquisitions could accelerate over the next few years as pipelines de-risk.
“I think this is going to create a fairly healthy M and A environment for the group.”at 18:12
Across the shows
What other episodes Chorus covered said about the same companies in the 30 days up to this one.
- Merck & Co.4 speakers · 3 bullish, 1 bearish calls
Topics
- AI in drug development
- China biotech innovation
- GLP-1 market growth
- GLP-1 pricing
- Medicaid and ACA coverage
- device adoption economics
- drug pricing policy
- innovation cycle
- medtech procedure volumes
- oncology drug innovation
- pharma M&A
- surgical robotics autonomy
More from J.P. Morgan Making Sense
- The rise of content as data: How AI is reshaping market insights · November 17, 2026
- Financing the Future of Defense: Admiral Pierre Vandier on Innovation and Investment · November 15, 2026
- Revving the ETF vehicle: Roundhill’s CEO on DRAM, next-gen innovation and more · November 13, 2026
- US midterms: Fiscal, market and geopolitical implications of the "blue wave" · November 9, 2026
- Rebuilding resilience in America’s pharmaceutical supply chain · November 8, 2026
Ask your AI about this episode
Chorus gives Claude, ChatGPT and other assistants every view from this episode and every other show Chorus follows. Ask who agrees, who changed their mind, and what else was said about the same companies.
Chorus reports what speakers said. It isn't investment advice. How Chorus works · About Chorus